CellWell record HH-538082
Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions
Zhen Wang; Yanqi Song; Aidi Wang; Baoshan Liu
2026
In plain language
In a phase 1 trial reviewed here, a dual-target antibody-drug conjugate produced a 63.2% response rate in 38 EGFR-mutated lung cancer patients, 34 of whom were resistant to prior TKI therapy.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-538082
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.